| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/30/2007 | US20070202157 Delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome |
| 08/30/2007 | US20070202133 BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| 08/30/2007 | US20070202115 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |
| 08/30/2007 | US20070202102 High-Yield Method For The Production Of Human Antibodies Blocking The Biological Activity Of A Human Cytokine |
| 08/30/2007 | US20070202101 Combination therapy using anti-EGFR antibodies and anti-hormonal agents |
| 08/30/2007 | US20070202100 Using programmed death-1 (PD-1) protein as evaluative tool to identify modulators for treatment and prevention of nervous system, autoimmune, cell proliferative and allergic disorders |
| 08/30/2007 | US20070202099 Antibody Drug |
| 08/30/2007 | DE102004055891B4 Gemische von Schlangengiften zur Krankheitsbekämpfung Mixtures of snake venoms disease control |
| 08/30/2007 | CA2643665A1 Indolopyridines as eg5 kinesin modulators |
| 08/30/2007 | CA2643603A1 Cytotoxicity mediation of cells evidencing surface expression of trop-2 |
| 08/30/2007 | CA2643561A1 Cancerous disease modifying antibody 141205-05 |
| 08/30/2007 | CA2643555A1 Cytotoxicity mediation of cells evidencing surface expression of cd59 |
| 08/30/2007 | CA2643488A1 Indolopyridines as eg5 kinesin modulators |
| 08/30/2007 | CA2643274A1 Oil-in-water emulsion composition containing licorice-derived polyphenol |
| 08/30/2007 | CA2643144A1 Cancerous disease modifying antibody 141205-04 |
| 08/30/2007 | CA2643059A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 08/30/2007 | CA2643056A1 Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases |
| 08/30/2007 | CA2642999A1 Dendritic cells transiently transfected with a membrane homing polypeptide and their use |
| 08/30/2007 | CA2642921A1 4-phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as plk1 inhibitors |
| 08/30/2007 | CA2642762A1 Pyrrolidine derivatives as erk inhibitors |
| 08/30/2007 | CA2642717A1 Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs |
| 08/30/2007 | CA2642243A1 Rapamycin derivatives for treating neuroblastoma |
| 08/30/2007 | CA2641661A1 Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists |
| 08/30/2007 | CA2640997A1 Doxorubicin formulations for anti-cancer use |
| 08/30/2007 | CA2638122A1 Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same |
| 08/30/2007 | CA2638095A1 New compounds |
| 08/30/2007 | CA2628253A1 Therapeutic anti-her2 antibody fusion polypeptides |
| 08/29/2007 | EP1826217A1 Method for identification of antigenic peptides |
| 08/29/2007 | EP1826205A1 Novel raloxifene succinic acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these |
| 08/29/2007 | EP1826198A1 Method for the synthesis of the sodium salt of retinoyl-cysteic acid and retinoyl-cysteine sulfinic acid |
| 08/29/2007 | EP1825859A1 Dendritic cells transiently transfected with a membrane homing polypeptide and their use |
| 08/29/2007 | EP1825857A1 Agent for ameliorating the maximum passage time through digestive tract, agent for ameliorating passage time through digestive tract and preventive for colon cancer |
| 08/29/2007 | EP1825852A1 ST104P as an anti-angiogenic agent |
| 08/29/2007 | EP1824975A2 Lna oligonucleotides and the treatment of cancer |
| 08/29/2007 | EP1824887A2 Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations |
| 08/29/2007 | EP1824886A2 Fully human monoclonal antibodies to il-13 |
| 08/29/2007 | EP1824863A1 Silicon compounds and their use |
| 08/29/2007 | EP1824862A1 Silicon compounds and their use |
| 08/29/2007 | EP1824856A1 2,4 (4,6) pyrimidine derivatives |
| 08/29/2007 | EP1824854A2 Substituted pteridines for treating inflammatory diseases |
| 08/29/2007 | EP1824849A2 Inhibitors of akt activity |
| 08/29/2007 | EP1824843A2 Inhibitors of protein kinases |
| 08/29/2007 | EP1824841A1 Substituted pyrrole derivative |
| 08/29/2007 | EP1824832A1 Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents |
| 08/29/2007 | EP1824818A2 2ALFA-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1ALFA-HYDROXYVITAMIN D3 AND THEIR USES |
| 08/29/2007 | EP1824564A2 Method for treating glioma |
| 08/29/2007 | EP1824509A2 Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy |
| 08/29/2007 | EP1824504A1 Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives |
| 08/29/2007 | EP1824503A1 Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation |
| 08/29/2007 | EP1824498A2 Methods and compositions for treating cellular proliferative diseases |
| 08/29/2007 | EP1824492A2 Cancer treatment method |
| 08/29/2007 | EP1824469A1 A method of modulating b cell functioning |
| 08/29/2007 | EP1725538B1 Pyridazinone ureas as antagonists of a4 integrins |
| 08/29/2007 | EP1644385B1 Silicon compounds and their use |
| 08/29/2007 | EP1604673B1 Auxiliary agent to be used in cancer therapy by dielectric heating and cancer therapy method |
| 08/29/2007 | EP1603930B1 Protein-bound derivatives of platinum complexes containing cyclobutane 1.1-dicarboxyllate ligands |
| 08/29/2007 | EP1450847A4 Apo2 ligand/trail formulations |
| 08/29/2007 | EP1423126B1 Treatment of hyperproliferative conditions of body surfaces |
| 08/29/2007 | EP1414961B1 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 08/29/2007 | EP1406907B1 Antitumoral derivatives of et-743 |
| 08/29/2007 | EP1404652B1 A novel alkaloid derivative and a pharmaceutical composition containing the same |
| 08/29/2007 | EP1351934B1 Naphthalene derivatives which bind to the ep4 receptor |
| 08/29/2007 | EP1337522B1 farnesyl protein transferase inhibitors |
| 08/29/2007 | EP1333840B9 M. tuberculosis chaperonin 60.1 and uses thereof |
| 08/29/2007 | EP1268431B1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| 08/29/2007 | EP1254162B1 Kahalalide f and related compounds |
| 08/29/2007 | EP1165781B1 Protease resistant flint analogs |
| 08/29/2007 | EP1140078B1 Benzimidazole vascular damaging agents |
| 08/29/2007 | EP1140024B1 Particles for oral delivery of peptides and proteins |
| 08/29/2007 | EP1032269B1 Treatment of neoplasms with interferon-sensitive, clonal viruses |
| 08/29/2007 | CN200939251Y Se-garlic capsules |
| 08/29/2007 | CN101027316A Tumor targeting agents and uses thereof |
| 08/29/2007 | CN101027309A Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer |
| 08/29/2007 | CN101027302A Pyrrolo-pyridine kinase modulators |
| 08/29/2007 | CN101027291A Benzimidazole derivatives and their use as cannabinoid receptor ligands |
| 08/29/2007 | CN101027290A Novel 2,3-phthalazinone derivatives, as AURORA-A kinase inhibitors |
| 08/29/2007 | CN101027099A Diagnostic marker for cancer |
| 08/29/2007 | CN101027070A Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer |
| 08/29/2007 | CN101027069A 神经酰胺酶抑制剂 Ceramidase inhibitor |
| 08/29/2007 | CN101027067A Antitumor composition |
| 08/29/2007 | CN101027059A Combination comprising ZD6474 and imatinib |
| 08/29/2007 | CN101027058A Cancer combination therapy comprising AZD2171 and imatinib |
| 08/29/2007 | CN101027055A Tricycles, their manufacture and use as pharmaceutical agents |
| 08/29/2007 | CN101027054A Inhibitors of HSP90 |
| 08/29/2007 | CN101027053A Inhibitors of HSP90 |
| 08/29/2007 | CN101027049A A pharmaceutical composition and its use |
| 08/29/2007 | CN101025419A Method for testing effect of angiogenesis inhibitor via integrin expression inhibition |
| 08/29/2007 | CN101024852A Biological conversion system of bufadienolide and use thereof |
| 08/29/2007 | CN101024842A Expression vectors encoding epitopes of target-associated antigens and its design method |
| 08/29/2007 | CN101024831A A tumor necrosis factor related ligand |
| 08/29/2007 | CN101024672A Novel ring-shape small-peptide BA and its use |
| 08/29/2007 | CN101024666A (1-arylseleno-3-triethyamino) glycerol tegafur thiophosphates compounds and its synthesization |
| 08/29/2007 | CN101024650A Eremophil-2-internal-ester diploymer having function of inhibiting tumor cell growth activity and use thereof |
| 08/29/2007 | CN101024647A Use of compound metabolized by diaporthe phaseolorum fungus |
| 08/29/2007 | CN101024644A Novel anti-tumor compound and its preparing method |
| 08/29/2007 | CN101024636A Eremophilane containing chlorine atom in Heizituowu and its anti-biotic and cell-toxin activity |
| 08/29/2007 | CN101024627A Nitrogen-containing aromatic derivatives |
| 08/29/2007 | CN101024622A Theanine amino-acid salt, its preparing method and use |
| 08/29/2007 | CN101024087A Chitosan and poly-piptide porphyrinl nano medicine carrier and its preparing and use |
| 08/29/2007 | CN101024031A Use of Rhizoma-paridis alcohol extract for inhibiting blood-vessel generation |